Biologics Safety Testing Market by Product & Service (Instruments, Consumables, Services), Application (mAbs, Vaccine, Cell & Gene Therapy), Test Type (Sterility Test, Endotoxin, Mycoplasma, Bioburden), End User (Biopharma, CDMO) - Global Forecast to 2027

Abstract
The global biologics safety testing market is projected to reach USD 6.8 billion by 2027 from USD 3.6 billion in 2022, at a CAGR of 13.3% during the forecast period. The growth of the global biologics safety testing market is driven by factors such as the strict regulatory scenario implemented for quality control testing for biopharmaceutical production, increase in the number of approved biologics products worldwide, growing use of biologics safety testing reagents and kits for cell culture contamination detection, and increases in R&D spending and government support will significantly boost biologics testing activities.

“By product & service segment, the service segment accounted for the largest share of the Biologics Safety Testing market”

Based on product and service, the biologics safety testing market is segmented into consumables, services, and instruments. In 2021, the services segment accounted for the largest market share. The large share of this segment can be attributed to large biopharmaceutical companies routinely outsource numerous tasks, such as process and product validation, process monitoring and quality control, toxicology, and other preclinical studies.

”By application, the monoclonal antibodies development and manufacturing segment accounted for the largest market share of the Biologics safety testing market “

Based on application, the biologics safety testing market is segmented into monoclonal antibodies development and manufacturing, vaccines development and manufacturing, blood and blood products development and manufacturing, cellular and gene therapy products development and manufacturing, and other applications. In 2021, the monoclonal antibodies development and manufacturing segment accounted for the largest market share. The large share of this segment can be attributed to the growing number of regulatory approvals.

“Asia Pacific: The fastest-growing region in the biologics safety testing market.”

The biologics safety testing market in the Asia Pacific region is projected to register the highest growth during the forecast period. Factors such as growth in the outsourcing industry in the Asia Pacific region, vastly expanding R&D funding by biopharmaceutical companies and government, minimized outsourcing costs, and rising patient population resulting in growing manufacturing of biologics are expected to drive market growth.

“North America accounted for the largest share of the Biologics safety testing market in 2021”

North America accounted for the largest share of the biologics safety testing market in 2021. Rapid growth in the biopharmaceutical industry is the major factor driving the growth of the North American biologics safety testing market. High number of pre-registration and other-phase drugs in the pipeline by pharmaceutical companies and biotechnology/gene therapy/genomics companies and the presence of major market players in this region are also driving the market for biologics safety testing in North America.

Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

•By Respondent– Supply Side- 80%, Demand Side-20%
•By Designation— CXOs - 20%, Executives - 25%, Mangers - 55%
•By Region— North America - 40%, Europe - 30%, APAC – 20%, LATAM & MEA- 10%

The Biologics Safety Testing market is dominated by a few globally established players such Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Labcorp (US), SGS SA (Switzerland), WuXi AppTec (China), Sartorius AG (Germany), Associates of Cape Cod, Inc. (US), bioMérieux SA (France), Eurofins Scientific (Luxembourg), FUJIFILM Wako Pure Chemical Corporation (Japan), Almac Group (UK), Bio-Rad Laboratories, Inc. (US), QIAGEN (Germany) , Pacific BioLabs (US), InvivoGen (US), Microcoat Biotechnologie GmbH (Germany), PromoCell GmbH (Germany), Samsung Biologics (South Korea), GenScript (China), Maravai Lifesciences (US), Accugen Laboratories, Inc. (US) and Nelson Laboratories, LCC (US)

Research Coverage:
The report segments the Biologics Safety Testing market based on region (Asia Pacific, Europe, North America, Latin America and Middle East and Africa), product and service (consumables, services, and instruments), application (monoclonal antibodies development and manufacturing, vaccines development and manufacturing, blood and blood products development and manufacturing, cellular and gene therapy products development and manufacturing, and other applications.), and test types (endotoxin tests, sterility tests, mycoplasma tests, bioburden tests, virus safety tests, residual host-cell proteins and DNA detection tests, and other biologics safety tests). The report also provides a comprehensive review of market drivers, opportunities, challenges and restrains in the Biologics Safety Testing market.

Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the Biologics Safety Testing market and provides them information on key market drivers, restraints, challenges, and opportunities.

Content
Table of Contents

1INTRODUCTION30
1.1STUDY OBJECTIVES30
1.2MARKET DEFINITION30
1.2.1INCLUSIONS AND EXCLUSIONS31
1.2.2MARKETS COVERED32
FIGURE 1BIOLOGICS SAFETY TESTING MARKET SEGMENTATION32
1.2.3YEARS CONSIDERED32
1.3CURRENCY CONSIDERED33
1.4LIMITATIONS33
1.5STAKEHOLDERS33
1.6SUMMARY OF CHANGES33
2RESEARCH METHODOLOGY35
2.1RESEARCH APPROACH35
FIGURE 2RESEARCH DESIGN35
2.1.1SECONDARY DATA36
2.1.2PRIMARY DATA37
FIGURE 3BREAKDOWN OF PRIMARIES: BIOLOGICS SAFETY TESTING MARKET37
2.1.3DATA TRIANGULATION APPROACH38
2.2DATA TRIANGULATION38
FIGURE 4DATA TRIANGULATION METHODOLOGY38
2.3MARKET ESTIMATION METHODOLOGY39
FIGURE 5MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION39
FIGURE 6MARKET SIZE ESTIMATION: SEGMENTAL ANALYSIS-BASED ESTIMATION39
FIGURE 7BIOLOGICS SAFETY TESTING MARKET: FINAL CAGR PROJECTION (2022−2027)40
FIGURE 8BIOLOGICS SAFETY TESTING: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES41
2.4INDUSTRY INSIGHTS42
2.5RESEARCH ASSUMPTIONS42
2.6RECESSION IMPACT42
TABLE 1GLOBAL INFLATION RATE PROJECTION, 2024−2027 (% GROWTH)42
3EXECUTIVE SUMMARY44
FIGURE 9BIOLOGICS SAFETY TESTING MARKET SHARE, BY PRODUCT & SERVICE (2021)44
FIGURE 10BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)45
FIGURE 11BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION)46
FIGURE 12BIOLOGICS SAFETY TESTING MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES47
4PREMIUM INSIGHTS48
4.1BIOLOGICS SAFETY TESTING MARKET OVERVIEW48
FIGURE 13RISING DEVELOPMENT OF BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET48
4.2NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION AND COUNTRY (2021)49
FIGURE 14MONOCLONAL ANTIBODIES MANUFACTURING SEGMENT ACCOUNTED FOR LARGEST SHARE IN 202149
4.3BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE50
FIGURE 15RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS SEGMENT TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD50
5MARKET OVERVIEW51
5.1MARKET DYNAMICS51
FIGURE 16BIOLOGICS SAFETY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES51
5.1.1DRIVERS52
5.1.1.1Growing development of biosimilars and biologics52
TABLE 2LIST OF BIOLOGICAL LICENSE APPLICATION APPROVALS IN US, 202152
TABLE 3LIST OF BIOLOGICS APPROVED BY US FDA (2021)53
5.1.1.2Growing concerns over cell culture contamination54
5.1.1.3Rising investments in biopharmaceutical R&D54
TABLE 4PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2020 VS. 2026 (USD BILLION)54
FIGURE 17PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE,
2017–202455
5.1.2RESTRAINTS55
5.1.2.1Shortage of skilled professionals55
5.1.3OPPORTUNITIES56
5.1.3.1Emerging markets56
5.1.3.2Increasing outsourcing of biopharmaceutical activities to CROs56
5.1.4CHALLENGES57
5.1.4.1High cost of biologics57
5.2PRICING ANALYSIS57
TABLE 5AVERAGE SELLING PRICE OF BIOLOGICS SAFETY TESTING PRODUCTS
(2020-2021)57
5.2.1PRICING TREND ANALYSIS57
5.3VALUE CHAIN ANALYSIS58
FIGURE 18BIOLOGICS SAFETY TESTING MARKET: VALUE CHAIN ANALYSIS58
5.4ECOSYSTEM ANALYSIS59
FIGURE 19BIOLOGICS SAFETY TESTING MARKET: ECOSYSTEM ANALYSIS59
5.5TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES59
FIGURE 20REVENUE SHIFT FOR BIOLOGICS SAFETY TESTING PROVIDERS59
5.6PATENT ANALYSIS60
FIGURE 21TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR BIOLOGICS SAFETY PATENTS (JANUARY 2012−NOVEMBER 2022)60
TABLE 6BIOLOGICS SAFETY TESTING MARKET: INDICATIVE LIST OF PATENTS61
5.7REGULATORY ANALYSIS62
5.7.1US62
5.7.2EUROPE63
5.7.3ASIA PACIFIC64
5.7.4LATIN AMERICA64
5.7.5MIDDLE EAST AND AFRICA64
5.7.6REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS65
TABLE 7NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS65
TABLE 8EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS65
TABLE 9ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS66
TABLE 10REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS66
5.8PORTER'S FIVE FORCES ANALYSIS67
TABLE 11BIOLOGICS SAFETY TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS67
5.8.1THREAT OF NEW ENTRANTS67
5.8.2THREAT OF SUBSTITUTES67
5.8.3BARGAINING POWER OF BUYERS67
5.8.4BARGAINING POWER OF SUPPLIERS68
5.8.5INTENSITY OF COMPETITIVE RIVALRY68
5.9KEY CONFERENCES AND EVENTS IN 2022–202368
TABLE 12BIOLOGICS SAFETY TESTING MARKET: CONFERENCES AND EVENTS68
5.10KEY STAKEHOLDERS AND BUYING CRITERIA69
FIGURE 22INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCTS & SERVICES69
FIGURE 23BUYING CRITERIA FOR BIOLOGICS SAFETY TESTING PRODUCTS & SERVICES69
6BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE70
6.1INTRODUCTION71
TABLE 13BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)71
6.2SERVICES71
6.2.1INCREASING OUTSOURCING OF SERVICES TO CROS TO DRIVE MARKET71
TABLE 14BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)72
TABLE 15NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)72
TABLE 16EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)72
TABLE 17ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)73
6.3CONSUMABLES73
6.3.1RECURRENT PURCHASE OF ASSAYS, KITS, AND REAGENTS TO DRIVE MARKET73
TABLE 18BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)74
TABLE 19NORTH AMERICA: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)74
TABLE 20EUROPE: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)74
TABLE 21ASIA PACIFIC: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)75
6.4INSTRUMENTS75
6.4.1LONGER SHELF LIFE OF INSTRUMENTS TO RESTRAIN MARKET75
TABLE 22BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)76
TABLE 23NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)76
TABLE 24EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)76
TABLE 25ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)77
7BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE78
7.1INTRODUCTION79
TABLE 26BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)79
7.2RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS79
7.2.1GROWING USE OF RDNA IN VARIOUS MANUFACTURING STAGES TO DRIVE MARKET79
TABLE 27RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)80
TABLE 28NORTH AMERICA: RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)80
TABLE 29EUROPE: RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)80
TABLE 30ASIA PACIFIC: RESIDUAL HOST-CELL PROTEINS AND DNA DETECTION TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)81
7.3MYCOPLASMA TESTS81
7.3.1GROWING CONCERNS OVER CELL CULTURE CONTAMINATION TO DRIVE MARKET81
TABLE 31MYCOPLASMA TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)82
TABLE 32NORTH AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)82
TABLE 33EUROPE: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)82
TABLE 34ASIA PACIFIC: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)83
7.4STERILITY TESTS83
7.4.1MANDATORY TESTING CONDUCTED FOR DRUG DEVELOPMENT & PRODUCTION TO DRIVE MARKET83
TABLE 35STERILITY TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)84
TABLE 36NORTH AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)84
TABLE 37EUROPE: STERILITY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)84
TABLE 38ASIA PACIFIC: STERILITY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)85
7.5ENDOTOXIN TESTS85
7.5.1RISING DEMAND FOR LAL TESTING TO SUPPORT MARKET GROWTH85
TABLE 39ENDOTOXIN TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)86
TABLE 40NORTH AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)86
TABLE 41EUROPE: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)86
TABLE 42ASIA PACIFIC: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)87
7.6VIRUS SAFETY TESTS87
7.6.1RISING UPTAKE IN VACCINE DEVELOPMENT AND CELL & GENE THERAPY TO SUPPORT MARKET87
TABLE 43VIRUS SAFETY TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)88
TABLE 44NORTH AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)88
TABLE 45EUROPE: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)88
TABLE 46ASIA PACIFIC: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)89
7.7BIOBURDEN TESTS89
7.7.1GROWING CONCERNS FOR DRUG SAFETY STANDARDS TO PROPEL MARKET89
TABLE 47BIOBURDEN TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)89
TABLE 48NORTH AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)90
TABLE 49EUROPE: BIOBURDEN TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)90
TABLE 50ASIA PACIFIC: BIOBURDEN TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)90
7.8OTHER BIOLOGICS SAFETY TESTS91
TABLE 51OTHER BIOLOGICS SAFETY TESTS MARKET, BY REGION, 2020–2027 (USD MILLION)91
TABLE 52NORTH AMERICA: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)91
TABLE 53EUROPE: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)92
TABLE 54ASIA PACIFIC: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)92
8BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION93
8.1INTRODUCTION94
TABLE 55BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)94
8.2MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING94
8.2.1RISING APPROVALS FOR BIOSIMILAR MABS TO DRIVE MARKET94
TABLE 56BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY REGION, 2020–2027 (USD MILLION)95
TABLE 57NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)95
TABLE 58EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)96
TABLE 59ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)96
8.3VACCINE DEVELOPMENT AND MANUFACTURING96
8.3.1GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET96
TABLE 60BIOLOGICS SAFETY TESTING MARKET FOR VACCINE DEVELOPMENT AND MANUFACTURING, BY REGION, 2020–2027 (USD MILLION)97
TABLE 61NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR VACCINE DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)97
TABLE 62EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR VACCINE DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)98
TABLE 63ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR VACCINE DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)98
8.4CELLULAR & GENE THERAPY PRODUCT DEVELOPMENT AND MANUFACTURING98
8.4.1RISING ADOPTION OF CELLULAR IMMUNOTHERAPIES FOR CANCER TREATMENT TO DRIVE MARKET98
TABLE 64BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCT DEVELOPMENT AND MANUFACTURING, BY REGION, 2020–2027 (USD MILLION)99
TABLE 65NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)99
TABLE 66EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCT DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)100
TABLE 67ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)100
8.5BLOOD & BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING100
8.5.1RISING UPTAKE OF STERILITY TESTS TO SUPPORT MARKET GROWTH100
TABLE 68BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING, BY REGION, 2020–2027 (USD MILLION)101
TABLE 69NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)101
TABLE 70EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)102
TABLE 71ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCT DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)102
8.6OTHER APPLICATIONS102
TABLE 72BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)103
TABLE 73NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)103
TABLE 74EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)104
TABLE 75ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)104
9BIOLOGICS SAFETY TESTING MARKET, BY END USER105
9.1INTRODUCTION106
TABLE 76BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)106
9.2PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES106
9.2.1GROWING R&D EXPENDITURE FOR DRUG DEVELOPMENT TO DRIVE MARKET106
FIGURE 24PHARMACEUTICAL R&D SPENDING (2014–2028)107
TABLE 77BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION)107
TABLE 78NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)108
TABLE 79EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)108
TABLE 80ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)108
9.3CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CROS AND CDMOS)109
9.3.1ABILITY TO PROVIDE SPECIALIZED MANUFACTURING AND SAFETY TESTING TECHNOLOGIES TO DRIVE MARKET109
TABLE 81BIOLOGICS SAFETY TESTING MARKET FOR CROS AND CDMOS, BY REGION, 2020–2027 (USD MILLION)109
TABLE 82NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CRS AND CDMOS, BY COUNTRY, 2020–2027 (USD MILLION)110
TABLE 83EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CROS AND CDMOS,
BY COUNTRY, 2020–2027 (USD MILLION)110
TABLE 84ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CROS AND CDMOS, BY COUNTRY, 2020–2027 (USD MILLION)110
9.4ACADEMIC & RESEARCH INSTITUTES111
9.4.1AVAILABILITY OF ADVANCED EQUIPMENT AND SPECIALIZED R&D PERSONNEL TO SUPPORT MARKET GROWTH111
TABLE 85BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)111
TABLE 86NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)112
TABLE 87EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)112
TABLE 88ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)112
10BIOLOGICS SAFETY TESTING MARKET, BY REGION113
10.1INTRODUCTION114
TABLE 89BIOLOGICS SAFETY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)114
10.2NORTH AMERICA114
FIGURE 25BIOLOGICS SAFETY TESTING MARKET: NORTH AMERICA MARKET SNAPSHOT115
TABLE 90NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)116
TABLE 91NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)116
TABLE 92NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)116
TABLE 93NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)117
TABLE 94NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)117
10.2.1US118
10.2.1.1High investments in biopharmaceutical R&D to drive market118
TABLE 95US: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)118
TABLE 96US: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE,
2020–2027 (USD MILLION)119
TABLE 97US: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION,
2020–2027 (USD MILLION)119
TABLE 98US: BIOLOGICS SAFETY TESTING MARKET, BY END USER,
2020–2027 (USD MILLION)120
10.2.2CANADA120
10.2.2.1Presence of R&D clusters and growing life sciences research to drive market120
TABLE 99CANADA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)121
TABLE 100CANADA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE,
2020–2027 (USD MILLION)121
TABLE 101CANADA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION,
2020–2027 (USD MILLION)122
TABLE 102CANADA: BIOLOGICS SAFETY TESTING MARKET, BY END USER,
2020–2027 (USD MILLION)122
10.2.3NORTH AMERICA: RECESSION IMPACT123
10.3EUROPE124
TABLE 103EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY,
2020–2027 (USD MILLION)124
TABLE 104EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)125
TABLE 105EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)125
TABLE 106EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)126
TABLE 107EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)126
10.3.1GERMANY127
10.3.1.1Favorable R&D funding by federal and state governments to propel market127
TABLE 108GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)127
TABLE 109GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)128
TABLE 110GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)128
TABLE 111GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)129
10.3.2UK129
10.3.2.1Growing focus on investments in vaccine manufacturing to drive market129
TABLE 112UK: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)130
TABLE 113UK: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)130
TABLE 114UK: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)131
TABLE 115UK: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)131
10.3.3FRANCE131
10.3.3.1Government initiatives to strengthen R&D activities to support market growth131
TABLE 116FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)132
TABLE 117FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)132
TABLE 118FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)133
TABLE 119FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)133
10.3.4ITALY134
10.3.4.1Favorable government support for establishment of biotech startups to propel market134
TABLE 120ITALY: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)134
TABLE 121ITALY: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)135
TABLE 122ITALY: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)135
TABLE 123ITALY: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)136
10.3.5SPAIN136
10.3.5.1Increasing biologics production and outsourcing testing services to support market growth136
TABLE 124SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)137
TABLE 125SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)137
TABLE 126SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)138
TABLE 127SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)138
10.3.6REST OF EUROPE138
TABLE 128REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)139
TABLE 129REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)139
TABLE 130REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)140
TABLE 131REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)140
10.3.7EUROPE: RECESSION IMPACT141
10.4ASIA PACIFIC141
FIGURE 26BIOLOGICS SAFETY TESTING MARKET: ASIA PACIFIC MARKET SNAPSHOT142
TABLE 132ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)143
TABLE 133ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)143
TABLE 134ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)143
TABLE 135ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)144
TABLE 136ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY END USERS, 2020–2027 (USD MILLION)144
10.4.1CHINA145
10.4.1.1Rising approvals for drug applications and high R&D innovation to drive market145
TABLE 137CHINA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)145
TABLE 138CHINA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)146
TABLE 139CHINA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)146
TABLE 140CHINA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)147
10.4.2JAPAN147
10.4.2.1Rising investments for establishment of cell & gene therapy facilities to propel market147
TABLE 141JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)147
TABLE 142JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)148
TABLE 143JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)148
TABLE 144JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)149
10.4.3INDIA149
10.4.3.1High demand for export of pharmaceuticals and vaccines to drive market149
TABLE 145INDIA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)150
TABLE 146INDIA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)150
TABLE 147INDIA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)151
TABLE 148INDIA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)151
10.4.4REST OF ASIA PACIFIC151
TABLE 149REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)152
TABLE 150REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)152
TABLE 151REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)153
TABLE 152REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)153
10.4.5ASIA PACIFIC: RECESSION IMPACT154
10.5LATIN AMERICA154
10.5.1GROWING APPROVAL OF BIOSIMILARS TO SUPPORT MARKET GROWTH154
TABLE 153LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)155
TABLE 154LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)155
TABLE 155LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)156
TABLE 156LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)156
10.5.2LATIN AMERICA: RECESSION IMPACT157
10.6MIDDLE EAST & AFRICA157
10.6.1RISING FOCUS ON DRUG DISCOVERY AND DEVELOPMENT TO SUPPORT MARKET GROWTH157
TABLE 157MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)158
TABLE 158MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)158
TABLE 159MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)159
TABLE 160MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)159
10.6.2MIDDLE EAST & AFRICA: RECESSION IMPACT159
11COMPETITIVE LANDSCAPE161
11.1OVERVIEW161
11.2RIGHT-TO-WIN STRATEGIES ADOPTED BY KEY PLAYERS161
FIGURE 27BIOLOGICS SAFETY TESTING MARKET: KEY PLAYER STRATEGIES (2019–2022)162
11.3MARKET SHARE ANALYSIS163
FIGURE 28BIOLOGICS SAFETY TESTING MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2021 (TOP EIGHT)163
TABLE 161BIOLOGICS SAFETY TESTING MARKET: INTENSITY OF COMPETITIVE RIVALRY164
11.4REVENUE SHARE ANALYSIS OF KEY PLAYERS165
FIGURE 29BIOLOGICS SAFETY TESTING MARKET: REVENUE SHARE ANALYSIS OF KEY PLAYERS (TOP EIGHT)165
11.5COMPANY EVALUATION MATRIX165
11.5.1STARS166
11.5.2EMERGING LEADERS166
11.5.3PERVASIVE PLAYERS166
11.5.4PARTICIPANTS166
FIGURE 30BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX, 2021167
11.6COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS167
11.6.1PROGRESSIVE COMPANIES167
11.6.2STARTING BLOCKS167
11.6.3DYNAMIC COMPANIES168
11.6.4RESPONSIVE COMPANIES168
FIGURE 31BIOLOGICS SAFETY TESTING: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS (2021)168
11.7COMPETITIVE BENCHMARKING169
11.7.1COMPANY PRODUCT FOOTPRINT169
TABLE 162BIOLOGICS SAFETY TESTING MARKET: PRODUCT PORTFOLIO ANALYSIS169
11.7.2COMPANY TEST TYPE FOOTPRINT170
TABLE 163BIOLOGICS SAFETY TESTING MARKET: TEST TYPE ANALYSIS170
11.7.3COMPANY GEOGRAPHIC FOOTPRINT171
TABLE 164BIOLOGICS SAFETY TESTING MARKET: GEOGRAPHIC ANALYSIS171
11.7.4OVERALL COMPANY FOOTPRINT (25 COMPANIES)172
TABLE 165BIOLOGICS SAFETY TESTING MARKET: COMPANY FOOTPRINT172
11.7.4.1COMPETITIVE BENCHMARKING FOR STARTUPS173
TABLE 166BIOLOGICS SAFETY TESTING MARKET: KEY STARTUPS173
TABLE 167BIOLOGICS SAFETY TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS174
11.8COMPETITIVE SCENARIO175
11.8.1BIOLOGICS SAFETY TESTING MARKET: PRODUCT LAUNCHES (JANUARY 2019−DECEMBER 2022)175
11.8.2BIOLOGICS SAFETY TESTING MARKET: DEALS (JANUARY 2019−DECEMBER 2022)176
11.8.3BIOLOGICS SAFETY TESTING MARKET: OTHER DEVELOPMENTS (JANUARY 2019−DECEMBER 2022)177
12COMPANY PROFILES178
12.1KEY PLAYERS178
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1CHARLES RIVER LABORATORIES178
TABLE 168CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW178
FIGURE 32CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2021)179
12.1.2LONZA184
TABLE 169LONZA: BUSINESS OVERVIEW184
FIGURE 33LONZA: COMPANY SNAPSHOT (2021)185
12.1.3THERMO FISHER SCIENTIFIC, INC.189
TABLE 170THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW189
FIGURE 34THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)190
12.1.4MERCK KGAA193
TABLE 171MERCK KGAA: BUSINESS OVERVIEW193
FIGURE 35MERCK KGAA: COMPANY SNAPSHOT (2021)194
12.1.5LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP)197
FIGURE 36LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)198
12.1.6SGS SA201
TABLE 173SGS SA: BUSINESS OVERVIEW201
FIGURE 37SGS SA: COMPANY SNAPSHOT (2021)202
12.1.7EUROFINS SCIENTIFIC204
TABLE 174EUROFINS SCIENTIFIC: BUSINESS OVERVIEW204
FIGURE 38EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)205
12.1.8WUXI APPTEC207
TABLE 175WUXI APPTEC: BUSINESS OVERVIEW207
FIGURE 39WUXI APPTEC: COMPANY SNAPSHOT (2021)208
12.1.9ASSOCIATES OF CAPE COD, INC.210
TABLE 176ASSOCIATES OF CAPE COD, INC.: BUSINESS OVERVIEW210
12.1.10BIOMÉRIEUX SA212
TABLE 177BIOMÉRIEUX SA: BUSINESS OVERVIEW212
FIGURE 40BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)213
12.1.11SAMSUNG BIOLOGICS215
TABLE 178SAMSUNG BIOLOGICS: BUSINESS OVERVIEW215
FIGURE 41SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2021)216
12.1.12GENSCRIPT218
TABLE 179GENSCRIPT: BUSINESS OVERVIEW218
FIGURE 42GENSCRIPT: COMPANY SNAPSHOT (2021)219
12.1.13SARTORIUS AG221
TABLE 180SARTORIUS AG: BUSINESS OVERVIEW221
FIGURE 43SARTORIUS AG: COMPANY SNAPSHOT (2021)222
12.1.14F. HOFFMANN-LA ROCHE LTD.224
TABLE 181F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW224
FIGURE 44F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)225
12.1.15PACIFIC BIOLABS227
TABLE 182PACIFIC BIOLABS: BUSINESS OVERVIEW227
12.1.16NELSON LABORATORIES, LLC (PART OF SOTERA HEALTH)229
TABLE 183NELSON LABORATORIES: BUSINESS OVERVIEW229
12.1.17AGILENT TECHNOLOGIES, INC.231
TABLE 184AGILENT TECHNOLOGIES: BUSINESS OVERVIEW231
FIGURE 45AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021)232
12.1.18MARAVAI LIFESCIENCES234
TABLE 185MARAVAI LIFESCIENCES: BUSINESS OVERVIEW234
FIGURE 46MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2021)235
12.2OTHER PLAYERS237
12.2.1QIAGEN237
12.2.2BIO-RAD LABORATORIES, INC.238
12.2.3MICROCOAT BIOTECHNOLOGIE GMBH239
12.2.4INVIVOGEN240
12.2.5PROMOCELL GMBH241
12.2.6ACCUGEN LABORATORIES, INC.242
12.2.7FUJIFILM WAKO PURE CHEMICAL CORPORATION242
12.2.8ALMAC GROUP243
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13APPENDIX244
13.1DISCUSSION GUIDE244
13.2KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL246
13.3CUSTOMIZATION OPTIONS248
13.4RELATED REPORTS248
13.5AUTHOR DETAILS249